Cardiovascular Pharmacology of NIP‐121, A Potassium Channel Opener

Yamashita, Torn; Masuda, Yuichi; Shikada, Ken-ichi; Tanaka, Sakuya

doi:10.1111/j.1527-3466.1995.tb00215.x

Cited by 5 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Benzofurazan analogues of the PCA levcromakalim (GlaxoSmithKline) were disclosed in a patent from Nissan Chemical Industries as therapeutic agents to treat hypertension and ischemic heart diseases (Figure ). The derivative NIP-121 was reported to have a more favorable activity profile than levcromakalim , (Table ). Preclinical investigation demonstrated dose-dependent reductions in systemic blood pressure; tachycardia was observed, but could be prevented by combination with a β-blocker .…”

Section: Hypertensionmentioning

confidence: 99%

Furazans in Medicinal Chemistry

et al. 2021

View full text Add to dashboard Cite

Incorporation of heterocycles into drug molecules can enhance physical properties and biological activity. A variety of heterocyclic groups is available to medicinal chemists, many of which have been reviewed in detail elsewhere. Oxadiazoles are a class of heterocycle containing one oxygen and two nitrogen atoms, available in three isomeric forms. While the 1,2,4- and 1,3,4-oxadiazoles have seen widespread application in medicinal chemistry, 1,2,5-oxadiazoles (furazans) are less common. This Review provides a summary of the application of furazan-containing molecules in medicinal chemistry and drug development programs from analysis of both patent and academic literature. Emphasis is placed on programs that reached clinical or preclinical stages of development. The examples provided herein describe the pharmacology and biological activity of furazan derivatives with comparative data provided where possible for other heterocyclic groups and pharmacophores commonly used in medicinal chemistry.

show abstract

Section: Hypertensionmentioning

confidence: 99%